Lineage Cell Therapeutics Inc. — Director's Dealing 2012

May 31, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-05-31

Reporting Person: WEST MICHAEL D (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-31	Common Shares, no par value	P	10000	$4.049	Acquired	109600	Direct

Footnotes

F1: The price of $4.049 per share represents a weighted average of prices ranging from $4.048 to $4.08 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F2: Does not include shares that may be acquired upon the exercise of certain stock options.